HAEGARDA safety and side effects

In a 32-week clinical trial, side effects for people taking HAEGARDA were usually mild

In clinical studies, the most common side effects reported with HAEGARDA were injection-site reactions (pain, redness, swelling), hypersensitivity (itching and rash), dizziness, and nasal symptoms, including stuffy or runny nose and sneezing. These are not the only side effects possible with HAEGARDA.

Shari, HAEGARDA advocate

HAE can be managed during pregnancy. Talk with your doctor about C1-INH when family planning.

  • There are no prospective clinical data from HAEGARDA use in pregnant women
  • A review of past pregnancies showed pregnant women with type 1 HAE received C1-INH doses of 500 or 1000 IU per I.V. administration for the treatment of acute attacks before, during, and/or after pregnancy (22 patients, 35 pregnancies)
  • Additionally, in an observational registry, data was collected on 11 pregnancies in 10 patients who received up to 3000 IU C1-INH (I.V. administration) doses to treat or prevent HAE attacks
  • No adverse events were associated with C1-INH treatment before, during, or after pregnancy

Before taking any HAE therapies, consult with your doctor if you are pregnant or considering becoming pregnant

COMMITTED TO QUALITY MANUFACTURING

We understand that you want the medications you take to meet the highest safety and quality standards. That’s why HAEGARDA goes through an advanced screening and purification process to reduce the risk of transmitting infection.

Our process includes:

  • Carefully selecting and screening US plasma donors
  • Thorough testing for viruses
  • Pasteurization (heat treatment for 10 hours)
  • Virus nanofiltration

We are committed to producing high-quality, safe and effective medicines. To us, that means that each step of the manufacturing process must meet or exceed the most stringent international standards for product safety in accordance with regulatory agencies worldwide.*

*The risk of transmission of infectious agents cannot be completely eliminated.

You are now leaving the current website.